Leaflet: information for the user
Lormetazepam pensa 1 mg tablets EFG
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
1. What is Lormetazepam Pensa and what is it used for
2. What you need to know before taking Lormetazepam Pensa
3. How to take Lormetazepam Pensa
4. Possible side effects
5. Storage of Lormetazepam Pensa
6. Contents of the pack and additional information
Lormetazepam Pensa is a medication from the group of hypnotics that promotes sleep: normalizes the time needed to fall asleep and its total duration, while reducing the number of interruptions of the same.
It is indicated for:
Lormetazepam Pensa belongs to a group of hypnotic medications called benzodiazepines. Benzodiazepines are only indicated for the treatment of an intense disorder, which limits the patient's activity or subjects them to an important stress situation.
Tolerance
Dependence
Rebound insomnia and anxiety
Amnesia
Psychiatric and paradoxical reactions
Inform your doctor or pharmacist if you are using or have recently used other medications, including those purchased without a prescription.
A potentiating effect of Lormetazepam Pensa may be produced when administered concomitantly with the following medications:
Consult your doctor if you are taking other medications.
Use of Lormetazepam Pensa with food and beverages
Benzodiazepines should be used with extreme caution in patients with a history of substance abuse or alcohol consumption. The sedative effect may be potentiated when the product is administered in combination with alcohol, so it is recommended to avoid the use of alcoholic beverages. This should be taken into account especially since it affects the ability to drive or operate machinery (see section "Driving and operating machines").
Pregnancy and lactation
Consult your doctor or pharmacist before using any medication.
As a general precaution, you should not use Lormetazepam during pregnancy, childbirth, or lactation.
If you are being treated with Lormetazepam and want to become pregnant or suspect that you are, consult your doctor to explain how you should stop treatment.
If, for strict medical reasons, the medication is administered during the third trimester of pregnancy, or at high doses during childbirth, it is predictable that there may be effects on the newborn such as hypothermia, hypotonia, and moderate respiratory depression.
Children born to mothers who take benzodiazepines chronically during the last trimester of pregnancy may develop physical dependence and trigger withdrawal syndrome in the postnatal period.
Due to the fact that benzodiazepines pass into breast milk, their use is contraindicated in lactating mothers.
Use in children and adolescents
Lormetazepam should not be administered to patients under 18 years of age for the treatment of insomnia without a careful evaluation of the need for it by the doctor. In addition, the duration of treatment should be the minimum possible. For more information on use in patients under 18 years, see section "3. HOW TO TAKE LORMETAZEPAM PENSA".
Use in the elderly
Elderly patients should receive a lower dose than usual. Your doctor will recommend the most suitable dosage. (See section "3. HOW TO TAKE LORMETAZEPAM PENSA").
Important information about some of the components of Lormetazepam Pensa
This medication contains lactose. If your doctor has indicated that you have an intolerance to certain sugars, consult with him before taking this medication.
Driving and operating machines
Lormetazepam Pensa is a medication that produces sleep. Do not drive or operate machines if you feel drowsy or if you notice that your attention and reaction time are reduced. Pay special attention to the start of treatment or if the dose is increased.
Follow exactly the administration instructions for lormetazepam indicated by your doctor. Consult your doctor or pharmacist if you have doubts. Remember to take your medication.
Your doctor will indicate the duration of your treatment with lormetazepam. Do not discontinue treatment prematurely, as it may not achieve the desired effect.
Short-term treatment of insomnia
The duration of treatment should be as short as possible. Generally, it varies between a few days and two weeks, with a maximum period, including a gradual dose reduction, of four weeks.
The tablets should be taken with a small amount of liquid a little before going to bed.
Adults
It is recommended to administer 1 lormetazepam Pensa 1 mg tablet or ½ of the alternative presentation of lormetazepam Pensa 2 mg, in a single dose.
In cases of severe or persistent insomnia, and always according to medical criteria, the dose can be increased to 2 mg.
Older adults
It is recommended to administer ½ tablet per day (0.5 mg of lormetazepam), as a single dose.
In older adults, benzodiazepines may be associated with a higher risk of falls due to muscle weakness, dizziness, drowsiness, and fatigue. Therefore, your doctor will indicate the dose that best suits your condition.
If you estimate that the action of lormetazepam is too strong or too weak, consult your doctor or pharmacist.
Induction of sleep in pre- and post-operative periods
The doses will depend on the patient's age, weight, and general condition.
Adults
It is recommended to administer a medium/daily dose of 2 mg of lormetazepam (from 0.5 to 3 mg).
Children
It is recommended to administer a dose of 0.5 to 1 mg of lormetazepam per day (from ½ to 1 lormetazepam Pensa 1 mg tablet).
Older adults and patients at risk
It is generally recommended to administer doses of 1 mg per day. One hour before the operation, it is recommended to administer half of these doses.
Consider reducing the dose for patients with mild or moderate respiratory difficulties or for patients with liver insufficiency.
If you take more lormetazepam Pensa than you should
Overdose does not represent a vital threat unless its administration is combined with other central nervous system depressants (including alcohol). In case of overdose, consider the possibility that the patient has ingested multiple products.
Overdosing with benzodiazepines generally manifests itself by different degrees of central nervous system depression, ranging from drowsiness to coma. In moderate cases, symptoms include drowsiness, confusion, and lethargy; in more serious cases, ataxia (alteration of movement coordination), hypotonia (muscle tone decrease), hypotension (low blood pressure), respiratory depression, rarely coma, and very rarely death may appear.
In case of accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount used.
In case of assistance at a care center, do not forget to bring this prospectus.
If you forgot to take lormetazepam Pensa
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with lormetazepam Pensa
Upon cessation of administration, the symptoms that led to the use of the medication may reappear, including restlessness, anxiety, insomnia, headaches, and sweating, so your doctor will indicate precisely how to gradually reduce the dose.
If you have any other doubts about the use of this product, ask your doctor or pharmacist.
Like all medicines, Lormetazepam Pensa can cause side effects, although not everyone will experience them.
If the dosage is not adapted to the individual conditions of each patient, side effects may appear due to excessive sedation and muscle relaxation.
The meaning of the frequencies of side effects shown below is as follows:
Very common:means that it is likely to occur in1 or more of every 10 people,
Common:means that it is likely to occur inbetween 1 and 10 of every 100 people.
Immune system disorders
Common:Angioedema (inflammatory disease that affects the skin and subcutaneous and submucosal tissue).
Mental and behavioral disorders
Common:Anxiety, decreased libido (sexual desire).
Nervous system disorders
Very common: Headache.
Common: Dizziness,sedation, somnolence (drowsiness), attention disorder, amnesia, visual disorder, speech disorder, dysgeusia, delayed thinking.
Cardiac disorders
Common:Tachycardia (acceleration of heartbeats).
Gastrointestinal disorders
Common:Vomiting, nausea, upper abdominal pain, constipation, dry mouth.
Skin and subcutaneous tissue disorders
Common:Pruritus (itching).
Renal and urinary disorders
Common:Urination disorder.
General disorders and administration site conditions
Common:Weakness, sweating.
For more information on the following points, see the section “Be careful with Lormetazepam Pensa”.
Dependence:
The administration of Lormetazepam (even at therapeutic doses) may induce the development of physical dependence; withdrawal of treatment may induce the development of a withdrawal or rebound phenomenon (see section “Be careful with Lormetazepam Pensa”). It may produce psychological dependence. Cases of abuse have been reported.
Mental and behavioral disorders
Nervous system disorders
Disorders of other organs and systems
With the administration of Lormetazepam Pensa, the following adverse reactions have been reported: daytime somnolence, emotional numbness, emotional disorder, decreased alertness, confusion, fatigue, headache, dizziness, muscle weakness, ataxia (alteration of movement coordination) or double vision. These effects appear predominantly at the beginning of treatment and usually disappear with repeated administration. Occasionally, jaundice (yellow discoloration of mucous membranes and skin) and skin reactions such as urticaria, pruritus, or skin rash have been reported.
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of the reach and sight of children.
Lormetazepam Pensa does not require special conditions for conservation.
Do not use Lormetazepam Pensa after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy.in case of doubt preguest your pharmacist how to dispose of the packaging and medicines you no longer need. In this way, you will help protect the environment.
Composition of Lormetazepam Pensa
Appearance of the product and contents of the packaging
Lormetazepam Pensa 1 mg tablets are presented in boxes containing blister packs with 30 tablets (standard pack) and 500 tablets (clinical pack). The tablets are white, round, and scored on one side. The score serves to divide the tablet into two equal halves.
Other presentations:
Lormetazepam Pensa 2 mg tablets, which are presented in boxes containing blister packs with 20 tablets (standard pack) and 500 tablets (clinical pack).
Only some pack sizes may be marketed.
Holder of the marketing authorization
Towa Pharmaceutical, S.A.
C/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Responsible for manufacturing
Kern Pharma, S.L.
Polígono Ind. Colón II
C/ Venus, 72
08228 Terrassa (Barcelona)
This leaflet was approved in February 2016
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.